The Next Quarter Podcast - Episode 10 - Ian Coyne with David Van Sickle

David, a medical anthropologist turned healthtech founder, shares how studying the global rise of asthma led him from field research and the CDC into building Propeller Health: one of the early “hardware + software” digital health companies putting sensors onto inhalers to understand respiratory disease in real time. He reflects on founder leadership lessons, why regulation mattered earlier than most teams expect, and what healthcare could look like by 2050 as measurement, personalization, and product development costs radically shift.

Highlights:

• David’s path in brief: Medical anthropology PhD; asthma/allergy research in India and US communities; CDC Epidemic Intelligence Service; co‑founded Propeller Health in 2010; later sold to ResMed; now advising, investing, and doing board work (including LifeArc).
• Why asthma (and why tech): A drive to understand what’s happening in communities “in the moment” and use real‑world data to improve individual care and enable population‑level public health interventions.
• Early Propeller realities: Built the first inhaler sensors for an era before today’s always‑connected smartphones – initially even using “dumb phone” SMS approaches that quickly became obsolete, forcing sharper thinking about where consumer tech adoption was heading.
• Leadership lessons that stuck: The idea won’t carry the business on its own – hiring and talent matter most; the founder’s job becomes an “energy source” for the team; and you have to learn to live with a constant gap between where you are and where you think you should be.
• The unusual early hire: Bringing in regulatory/quality early and building the QMS helped Propeller navigate 510(k) clearance quickly at a time when hardware‑software devices were still a bet in the market.
• 2050: where the biggest change comes from: Linear gains from better‑designed interventions, but potentially exponential gains from understanding exposures – the environmental, dietary, and contextual factors that may unlock long‑standing riddles like allergy, autoimmunity, and disease onset.
• Tech’s role (beyond “AI will solve it”): A future built on richer “life‑course” measurement – from birth to death – and cheaper, faster ways to build and ship medtech/diagnostics products without needing to capitalize massive companies each time.
• A “Cambrian explosion” of micro‑products: As build costs fall, expect more niche devices and diagnostics, more personalization, and more experimentation in smaller markets – mirroring what software did to product creation.
• If he could reinvent one thing: Ultrasound – still underused due to training and manual complexity – could become far more ubiquitous if made smarter, more automated, and easier to deploy in the field.
• Founder pattern-matching: He’s drawn to “oddball misfits” deeply coupled to a real problem over time – less excited by businesses that simply monetize dysfunction in healthcare delivery.
• Moonshot: Create a working model to get incremental clinician‑invented tools out of universities and hospitals and into the market – because most valuable ideas aren’t venture‑backable, and tech transfer often leaves them on the shelf.
• Personal note: At seven, David thought he’d be a drummer – and he’s now playing music again, closing the loop on an early ambition

The Next Quarter is brought to you by Coulter Partners, the leadership advisory and executive search firm building teams that change the world.